This is the first controlled pharmacologic study to demonstrate that treatment of obesity improved PsA disease measures
The privately held biotech brings a first-in-class oncology program focused on small molecule–targeted protein degradation
The approval follows robust data from the SWIFT and ANCHOR Phase III trials
SLE remains a life-threatening autoimmune disease, with patients facing an elevated risk of early mortality and long-term organ damage
Diffuse large B-cell lymphoma (DLBCL), the most common type of non-Hodgkin lymphoma (NHL) in adults, represents 40% of all cases worldwide
India should explore Sustainability-Linked Incentives (SLI) targeting innovations in the 12 principles of green chemistry
The FDA acknowledged that Corcept’s pivotal GRACE trial met its primary endpoint and that data from the GRADIENT trial offered confirmatory evidence
The company’s consolidated revenue from operations rose to Rs. 361.13 crore in Q2 FY26 and Rs. 707.67 crore for the first half
The accelerated review covers WCK 5222 for multiple critical infections
The applications aim to launch Phase Ib/II trials for relapsed/refractory multiple myeloma and primary plasma cell leukemia, respectively
Subscribe To Our Newsletter & Stay Updated
